DOCSLIB.ORG

Q How Effective Is Spironolactone for Treating Resistant Hypertension?

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Q How Effective Is Spironolactone for Treating Resistant Hypertension? Evidence-based answers from the Family Physicians Inquiries Network CLINICAL INQUIRIES ONLINE EXCLUSIVE Corey Lyon, DO; Brigitte Utter, MD Q How effective is University of Colorado Family Medicine Residency, Denver spironolactone for treating Kristen DeSanto, MSLS, MS, RD University of Colorado resistant hypertension? Health Sciences Library, Denver EVIDENCE-BASED ANSWER DEPUTY EDITOR Rick Guthmann, MD, very effective. Spironolactone taking 3 or more medications (strength of MPH reduces systolic blood pressure recommendation [SOR]: C, meta-analysis Advocate Illinois Masonic A Family Medicine Residency, (SBP) by 11 to 17 mm Hg and diastolic of randomized controlled trials [RCTs] of Chicago blood pressure (DBP) by up to 6 mm Hg disease-oriented evidence). in patients with resistant hypertension Evidence summary with placebo (SBP: WMD = −10.8 mm Hg; A 2017 meta-analysis of 4 RCTs (869 pa- 95% CI, −13.16 to −8.43 mm Hg; DBP: WMD tients) evaluated the effectiveness of pre- = −4.62 mm Hg; 95% CI, −6.05 to −3.2 mm Hg; scribing spironolactone for patients with I2 = 35%), confirming that the excluded trial resistant hypertension, defined as above- was the source of heterogeneity in the initial goal blood pressure (BP) despite treatment analysis and that spironolactone continued with at least 3 BP-lowering drugs (at least 1 to significantly lower BP for the treatment of which was a diuretic).1 All 4 trials com- group compared with controls. pared spironolactone 25 to 50 mg/d with placebo. Follow-up periods ranged from 8 to Add-on treatment with spironolactone 16 weeks. The primary outcomes were sys- also reduces BP tolic and diastolic BPs, which were evaluated A 2016 meta-analysis of 5 RCTs with a total in the office, at home, or with an ambulatory of 553 patients examined the effectiveness monitor. of add-on treatment with spironolactone (25-50 mg/d) for patients with resistant Spironolactone markedly lowers hypertension, defined as failure to achieve systolic and diastolic BP BP < 140/90 mm Hg despite treatment A statistically significant reduction in SBP oc- with 3 or more BP-lowering drugs, in- curred in the spironolactone group compared cluding one diuretic.2 Spironolactone was with the placebo group (weighted mean dif- compared with placebo in 4 trials and ference [WMD] = −16.7 mm Hg; 95% confi- with ramipril in the remaining study. The dence interval [CI], −27.5 to −5.8 mm Hg). follow-up periods were 8 to 16 weeks. DBP also decreased (WMD = −6.11 mm Hg; Researchers separated BP outcomes into 95% CI, −9.34 to −2.88 mm Hg). 24-hour ambulatory systolic/diastolic BPs Because significant heterogeneity was and office systolic/diastolic BPs. found in the initial pooled results (I2 = 96% The 24-hour ambulatory BPs were sig- for SBP; I2 = 85% for DBP), investigators per- nificantly lower in the spironolactone group formed an analysis that excluded a single compared with the control group (24-hour study with a small sample size. The re-anal- SBP: WMD = −10.5 mm Hg; 95% CI, −12.3 to ysis continued to show significant reductions −8.71 mm Hg; 24-hour DBP: WMD = −4.09 in SBP and DBP for spironolactone compared mm Hg; 95% CI, −5.28 to −2.91 mm Hg). CONTINUED MDEDGE.COM/FAMILYMEDICINE VOL 68, NO 5 | JUNE 2019 | THE JOURNAL OF FAMILY PRACTICE E11 CLINICAL INQUIRIES No significant heterogeneity was noted in compared with alternative drug groups these analyses. (WMD = −4.5 mm Hg; 95% CI, −4.63 to −4.37 Office-based BPs also were markedly mm Hg), but alternative drugs reduced home reduced in spironolactone groups compared DBP significantly more than spironolactone with controls (office SBP: WMD = −17 mm Hg; (WMD = 0.6 mm Hg; 95% CI, 0.55-0.65 95% CI, −25 to −8.95 mm Hg); office DBP: mm Hg). Marked heterogeneity was found WMD = −6.18 mm Hg; 95% CI, −9.3 to −3.05 in these analyses, and the authors also noted mm Hg). Because the office-based BP data that reductions in SBP are more clinically rel- showed significant heterogeneity (I2 = 94% evant than decreases in DBP. for SBP and 84.2% for DBP), 2 studies deter- mined to be of lower quality caused by lack of detailed methodology were excluded from Recommendations analysis, yielding continued statistically sig- The 2017 American Heart Association/ nificant reductions in SBP (WMD = −11.7 American College of Cardiology evidence- mm Hg; 95% CI, −14.4 to −8.95 mm Hg) and based guideline recommends considering DBP (WMD = −4.07 mm Hg; 95% CI, −5.6 to adding a mineralocorticoid receptor agonist −2.54 mm Hg) compared with controls. Het- to treatment regimens for resistant hyperten- erogeneity also decreased when the 2 studies sion when: office BP remains ≥ 130/80 mm Hg; were excluded (I2 = 21% for SBP and I2 = 59% the patient is prescribed at least 3 antihyper- Spironolactone for DBP). tensive agents at optimal doses including a reduces systolic diuretic; pseudoresistance (nonadherence, blood pressure How spironolactone compares inaccurate measurements) is excluded; re- by 11 to 17 with alternative drugs versible lifestyle factors have been addressed; mm Hg and A 2017 meta-analysis of 5 RCTs with 662 substances that interfere with BP treatment diastolic blood patients evaluated the effectiveness of spi- (such as nonsteroidal anti-inflammatory pressure by ronolactone (25-50 mg/d) on resistant hy- drugs and oral contraceptive pills) are up to 6 mm Hg pertension in patients taking 3 medications excluded; and screening for secondary 4 in patients compared with a control group—placebo causes of hypertension is complete. in 3 trials, placebo or bisoprolol (5-10 mg) The United Kingdom’s National Insti- with resistant in 1 trial, and an alternative treatment (can- tute for Health and Care Excellence (NICE) hypertension desartan 8 mg, atenolol 100 mg, or alpha evidence-based guideline recommends con- taking 3 or more methyldopa 750 mg) in 1 trial.3 Follow-up sidering spironolactone 25 mg/d to treat medications. periods ranged from 4 to 16 weeks. Research- resistant hypertension if the patient’s potas- ers evaluated changes in office and 24-hour sium level is 4.5 mmol/L or lower and BP is ambulatory or home BP and completed higher than 140/90 mm Hg despite treatment separate analyses of pooled data for spirono- with an optimal or best-tolerated dose of lactone compared with placebo groups, and an angiotensin-converting enzyme inhibi- spironolactone compared with alternative tor or angiotensin II receptor blocker plus a treatment groups. calcium-channel blocker and diuretic.5 Investigators found a statistically signifi- cant reduction in office SBP and DBP among Editor’s takeaway patients taking spironolactone compared The evidence from multiple RCTs convincing- with control groups (SBP: WMD = −15.7 ly shows the effectiveness of spironolactone. mm Hg; 95% CI, −20.5 to −11 mm Hg; DBP: Despite the SOR of C because of a disease- WMD = −6.21 mm Hg; 95% CI, −8.33 to oriented outcome, we do treat to blood pres- −4.1 mm Hg). A significant decrease also sure goals, and therefore, spironolactone is a occurred in 24-hour ambulatory home SBP good option. JFP and DBP (SBP: MD = −8.7 mm Hg; 95% CI, −8.79 to −8.62 mm Hg; DBP: WMD = −4.12 mm Hg; 95% CI, −4.48 to −3.75 mm Hg). References Patients treated with spironolactone 1. Zhao D, Liu H, Dong P, et al. A meta-analysis of add-on use of spi- ronolactone in patients with resistant hypertension. Int J Cardiol. showed a marked decrease in home SBP 2017;233:113-117. E12 THE JOURNAL OF FAMILY PRACTICE | JUNE 2019 | VOL 68, NO 5 2. Wang C, Xiong B, Huang J. Efficacy and safety of spironolac- blood pressure in adults: a report of the American College of tone in patients with resistant hypertension: a meta-analysis of Cardiology/American Heart Association Task Force on Clinical randomised controlled trials. Heart Lung Circ. 2016;25:1021-1030. Practice Guidelines. Hypertension. 2017. https://doi.org/10.1161 /HYP.0000000000000065. Accessed June 6, 2019. 3. Liu L, Xu B, Ju Y. Addition of spironolactone in patients with re- sistant hypertension: a meta-analysis of randomized controlled 5. National Institute for Health and Care Excellence. Hyperten- trials. Clin Exp Hypertens. 2017;39:257-263. sion in adults: diagnosis and management. Clinical guideline [CG127]. August 2011. https://www.nice.org.uk/guidance 4. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ /cg127/chapter/1-guidance#initiating-and-monitoring- ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for antihypertensive-drug-treatment-including-blood-pressure- the prevention, detection, evaluation, and management of high targets-2. Accessed June 6, 2019. MDEDGE.COM/FAMILYMEDICINE VOL 68, NO 5 | JUNE 2019 | THE JOURNAL OF FAMILY PRACTICE E13.
Load more

Recommended publications
  • Suitability of Immobilized Systems for Microbiological Degradation of Endocrine Disrupting Compounds
    molecules Review Suitability of Immobilized Systems for Microbiological Degradation of Endocrine Disrupting Compounds Danuta Wojcieszy ´nska , Ariel Marchlewicz and Urszula Guzik * Institute of Biology, Biotechnology and Environmental Protection, Faculty of Natural Science, University of Silesia in Katowice, Jagiello´nska28, 40-032 Katowice, Poland; [email protected] (D.W.); [email protected] (A.M.) * Correspondence: [email protected]; Tel.: +48-3220-095-67 Academic Editors: Urszula Guzik and Danuta Wojcieszy´nska Received: 10 September 2020; Accepted: 25 September 2020; Published: 29 September 2020 Abstract: The rising pollution of the environment with endocrine disrupting compounds has increased interest in searching for new, effective bioremediation methods. Particular attention is paid to the search for microorganisms with high degradation potential and the possibility of their use in the degradation of endocrine disrupting compounds. Increasingly, immobilized microorganisms or enzymes are used in biodegradation systems. This review presents the main sources of endocrine disrupting compounds and identifies the risks associated with their presence in the environment. The main pathways of degradation of these compounds by microorganisms are also presented. The last part is devoted to an overview of the immobilization methods used for the purposes of enabling the use of biocatalysts in environmental bioremediation. Keywords: EDCs; hormones; degradation; immobilization; microorganisms 1. Introduction The development of modern tools for the separation and identification of chemical substances has drawn attention to the so-called micropollution of the environment. Many of these contaminants belong to the emergent pollutants class. According to the Stockholm Convention they are characterized by high persistence, are transported over long distances in the environment through water, accumulate in the tissue of living organisms and can adversely affect them [1].
    [Show full text]
  • SPIRONOLACTONE Spironolactone – Oral (Common Brand Name
    SPIRONOLACTONE Spironolactone – oral (common brand name: Aldactone) Uses: Spironolactone is used to treat high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. It is also used to treat swelling (edema) caused by certain conditions (e.g., congestive heart failure) by removing excess fluid and improving symptoms such as breathing problems. This medication is also used to treat low potassium levels and conditions in which the body is making too much of a natural chemical (aldosterone). Spironolactone is known as a “water pill” (potassium-sparing diuretic). Other uses: This medication has also been used to treat acne in women, female pattern hair loss, and excessive hair growth (hirsutism), especially in women with polycystic ovary disease. Side effects: Drowsiness, lightheadedness, stomach upset, diarrhea, nausea, vomiting, or headache may occur. To minimize lightheadedness, get up slowly when rising from a seated or lying position. If any of these effects persist or worsen, notify your doctor promptly. Tell your doctor immediately if any of these unlikely but serious side effects occur; dizziness, increased thirst, change in the amount of urine, mental/mood chances, unusual fatigue/weakness, muscle spasms, menstrual period changes, sexual function problems. This medication may lead to high levels of potassium, especially in patients with kidney problems. If not treated, very high potassium levels can be fatal. Tell your doctor immediately if you notice any of the following unlikely but serious side effects: slow/irregular heartbeat, muscle weakness. Precautions: Before taking spironolactone, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies.
    [Show full text]
  • Homeopathy and Psychological Therapies
    Entry Homeopathy and Psychological Therapies Davide Donelli * and Michele Antonelli AUSL-IRCCS Reggio Emilia, 42122 Reggio Emilia, Italy; [email protected] * Correspondence: [email protected] Definition: Homeopathy is a popular, although highly debated, medicinal practice based on the administration of remedies in which active substances are so diluted that no detectable trace of them remains in the final product. This hypothesis paper aims to outline a possible reinterpreta- tion of homeopathy in the light of psychological therapies in order to improve its clinical safety and sustainability. Keywords: homeopathy; psychology; reinterpretation; hypothesis 1. Introduction Homeopathy is a popular, although highly debated, medicinal practice. In Italy, for ex- ample, it is estimated that, even if with a slightly declining trend, around 4.1% of the entire population (almost 2.5 million people) occasionally or regularly seeks homeopathic care, and these data, collected in 2013, suggest that homeopathy is the most used Complemen- tary and Alternative Medicine (CAM) by Italians [1]. Epidemiological studies aimed to assess the worldwide prevalence of homeopathy use have reported similar data for other high-income countries [2]. Homeopathy was first invented by the German doctor Samuel Hahnemann (1755–1843), and it is based on the administration of remedies in which active substances are so diluted that no detectable trace of them remains in the final product [3]. In his empirical studies, Citation: Donelli, D.; Antonelli, M. Hahnemann reported that the self-administration of a common antimalarial medicinal Homeopathy and Psychological Ther- plant (Cinchona) resulted in the occurrence of the same symptoms of malaria, but to a Encyclopedia 2021 1 apies.
    [Show full text]
  • Ocps) Used in the NM Family Planning Program (FPP
    The following slides are intended to familiarize nurses and clinicians with oral contraceptive pills (OCPs) used in the NM Family Planning Program (FPP). The FPP does not intend for this information to supersede the Family Planning Protocol particularly on the requirement for Public Health Nurses in the Public Health Offices to consult a clinician as stated in the Protocol when in doubt or if it is necessary to switch the client’s OCP type. 1 2 Combined oral contraceptives (COCs) contain two hormones; estrogen and progestin. In general, any combined OCP is good for most women who are eligible to take estrogen according to the CDC U.S. Medical Eligibility Criteria (MEC). Once again, refer to the US MEC chart to find out if OCP is a suitable choice for clients with specific health conditions. To learn a little bit about what each hormone does, the FPP is providing the following summary: Estrogen: provides endometrial stability = menstrual cycle control. A higher estrogen dose increases the venous thromboembolism (VTE) or clot risk but OCP clot risk is still less harmful than the clot risk related to pregnancy and giving birth. Progestin: provides most of the contraceptive effect by ‐Preventing luteinizing hormone (LH) surge /ovulation ‐Thickening the cervical mucus to prevent sperm entry. Two major OCP formations are available. Monophasic: There is only one dose of estrogen and progestin in each active pill in the packet; and Multiphasic: There are varying doses of hormones, particularly progestin in the active pills. 3 Section 3 of the FPP Protocol contains the OCP Substitute Table, which groups OCPs into 6 classes according to the estrogen dosage, the type of progestin and the formulations.
    [Show full text]
  • Nicotine and Behavioral Markers of Risk for Schizophrenia: a Double-Blind, Placebo- Controlled, Cross-Over Study Lana Dépatie, M.Sc., Gillian A
    Nicotine and Behavioral Markers of Risk for Schizophrenia: A Double-Blind, Placebo- Controlled, Cross-Over Study Lana Dépatie, M.Sc., Gillian A. O’Driscoll, Ph.D., Anne-Lise V. Holahan, B.Sc., Victoria Atkinson, R.N., Joseph X. Thavundayil, M.D., N. Ng Ying Kin, Ph.D., and Samarthji Lal, M.D. We investigated the effect of nicotine on three behavioral groups. A Drug ϫ Monitoring condition interaction (p Ͻ .01) markers of risk for schizophrenia: sustained attention on pursuit gain indicated that nicotine significantly (using the Continuous Performance Task (CPT)), increased pursuit gain in the no-monitoring condition in antisaccade performance, and smooth pursuit. Smooth patients and controls equally, but did not improve pursuit pursuit was investigated in two conditions, one in which in the monitoring condition. Thus, improvement in pursuit attention was enhanced (monitoring target changes) and may have been mediated via an effect on attention rather one in which attention was not enhanced (no monitoring). than by an effect on oculomotor function per se. In patients, Patients with schizophrenia (n ϭ 15) and controls (n ϭ 14) the magnitude of improvement in attention on nicotine was were given a 14-mg nicotine patch in a double-blind, correlated with the improvement on eye movement tasks. placebo-controlled, crossover design and plasma nicotine Thus, nicotine improves performance on both attention and concentrations were monitored. Nicotine concentrations oculomotor markers of risk for schizophrenia, possibly via were similar in both groups. A Group ϫ Drug interaction common mechanisms. (p Ͻ .02) on CPT hits indicated that nicotine improved [Neuropsychopharmacology 27:1056–1070, 2002] sustained attention in patients but not in controls.
    [Show full text]
  • Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals
    Journal of Clinical Medicine Review Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals Carlotta Cocchetti 1, Jiska Ristori 1, Alessia Romani 1, Mario Maggi 2 and Alessandra Daphne Fisher 1,* 1 Andrology, Women’s Endocrinology and Gender Incongruence Unit, Florence University Hospital, 50139 Florence, Italy; [email protected] (C.C); jiska.ristori@unifi.it (J.R.); [email protected] (A.R.) 2 Department of Experimental, Clinical and Biomedical Sciences, Careggi University Hospital, 50139 Florence, Italy; [email protected]fi.it * Correspondence: fi[email protected] Received: 16 April 2020; Accepted: 18 May 2020; Published: 26 May 2020 Abstract: Introduction: To date no standardized hormonal treatment protocols for non-binary transgender individuals have been described in the literature and there is a lack of data regarding their efficacy and safety. Objectives: To suggest possible treatment strategies for non-binary transgender individuals with non-standardized requests and to emphasize the importance of a personalized clinical approach. Methods: A narrative review of pertinent literature on gender-affirming hormonal treatment in transgender persons was performed using PubMed. Results: New hormonal treatment regimens outside those reported in current guidelines should be considered for non-binary transgender individuals, in order to improve psychological well-being and quality of life. In the present review we suggested the use of hormonal and non-hormonal compounds, which—based on their mechanism of action—could be used in these cases depending on clients’ requests. Conclusion: Requests for an individualized hormonal treatment in non-binary transgender individuals represent a future challenge for professionals managing transgender health care. For each case, clinicians should balance the benefits and risks of a personalized non-standardized treatment, actively involving the person in decisions regarding hormonal treatment.
    [Show full text]
  • Estrogen Actions Throughout the Brain
    Estrogen Actions Throughout the Brain BRUCE MCEWEN Harold and Margaret Milliken Hatch Laboratory of Neuroendocrinology, The Rockefeller University, New York, New York 10021 ABSTRACT Besides affecting the hypothalamus and other brain areas related to reproduction, ovarian steroids have widespread effects throughout the brain, on serotonin pathways, catecholaminergic neurons, and the basal forebrain cholinergic system as well as the hippocampal formation, a brain region involved in spatial and declarative memory. Thus, ovarian steroids have measurable effects on affective state as well as cognition, with implications for dementia. Two actions are discussed in this review; both appear to involve a combination of genomic and nongenomic actions of ovarian hormones. First, regulation of the serotonergic system appears to be linked to the presence of estrogen- and progestin-sensitive neurons in the midbrain raphe as well as possibly nongenomic actions in brain areas to which serotonin neurons project their axons. Second, ovarian hormones regulate synapse turnover in the CA1 region of the hippocampus during the 4- to 5-day estrous cycle of the female rat. Formation of new excitatory synapses is induced by estradiol and involves N-methyl-D-aspartate (NMDA) receptors, whereas downregulation of these synapses involves intracellular progestin receptors. A new, rapid method of radioimmunocytochemistry has made possible the demonstration of synapse formation by labeling and quantifying the specific synaptic and dendritic molecules involved. Although NMDA receptor activation is required for synapse formation, inhibitory interneurons may play a pivotal role as they express nuclear estrogen receptor-alpha (ER␣). It is also likely that estrogens may locally regulate events at the sites of synaptic contact in the excitatory pyramidal neurons where the synapses form.
    [Show full text]
  • Demystifying the Placebo Effect
    City University of New York (CUNY) CUNY Academic Works All Dissertations, Theses, and Capstone Projects Dissertations, Theses, and Capstone Projects 9-2018 Demystifying the Placebo Effect Phoebe Friesen The Graduate Center, City University of New York How does access to this work benefit ou?y Let us know! More information about this work at: https://academicworks.cuny.edu/gc_etds/2775 Discover additional works at: https://academicworks.cuny.edu This work is made publicly available by the City University of New York (CUNY). Contact: [email protected] DEMYSTIFYING THE PLACEBO EFFECT by PHOEBE FRIESEN A dissertation submitted to the Graduate Faculty in Philosophy in partial fulfillment of the requirements for the degree of Doctor of Philosophy, The City University of New York 2018 © 2018 PHOEBE FRIESEN All Rights Reserved ii Demystifying the Placebo Effect by Phoebe Friesen This manuscript has been read and accepted for the Graduate Faculty in Philosophy in satisfaction of the dissertation requirement for the degree of Doctor of Philosophy. ___________ ____________________________________ Date [Peter Godfrey-Smith] Chair of Examining Committee ___________ ____________________________________ Date [Nickolas Pappas ] Executive Office Supervisory Committee: Peter Godfrey-Smith Jesse Prinz John Greenwood THE CITY UNIVERSITY OF NEW YORK iii ABSTRACT Demystifying the Placebo Effect by Phoebe Friesen Advisor: Peter Godfrey-Smith This dissertation offers a philosophical analysis of the placebo effect. After offering an overview of recent evidence concerning the phenomenon, I consider several prominent accounts of the placebo effect that have been put forward and argue that none of them are able to adequately account for the diverse instantiations of the phenomenon. I then offer a novel account, which suggests that we ought to think of the placebo effect as encompassing three distinct responses: conditioned placebo responses, cognitive placebo responses, and network placebo responses.
    [Show full text]
  • Placebo-Controlled Trials of New Drugs: Ethical Considerations
    Reviews/Commentaries/Position Statements COMMENTARY Placebo-Controlled Trials of New Drugs: Ethical Considerations DAVID ORENTLICHER, MD, JD als, placebo controls are not appropriate when patients’ health would be placed at significant risk (8–10). A placebo- controlled study for a new hair- uch controversy exists regarding sufficiently more effective than placebo to thickening agent could be justified; a the ethics of placebo-controlled justify its use. Finally, not all established placebo-controlled study for patients M trials in which an experimental therapies have been shown to be superior with moderate or severe hypertension therapy will compete with an already es- to placebo. If newer drugs are compared would not be acceptable (11). Similarly, if tablished treatment (or treatments). In with the unproven existing therapies, an illness causes problems when it goes such cases, argue critics, patients in the then patients may continue to receive untreated for a long period of time, a 52- control arm of the study should receive an drugs that are harmful without being week study with a placebo control is accepted therapy rather than a placebo. helpful. much more difficult to justify than a By using an active and effective drug, the Moreover, say proponents of placebo 6-week study (12). control patients would not be placed at controls, patients can be protected from When David S.H. Bell (13) explains risk for deterioration of their disease, and harm by “escape” criteria, which call for why placebo controls are unacceptable the study would generate more meaning- withdrawal from the trial if the patient for new drugs to treat type 2 diabetes, he ful results for physicians.
    [Show full text]
  • Homeopathy Is Marketed As a Safe, Natural and Holistic Treatment for a Range of Ailments and Illnesses, Including Another Way of Saying
    sense about... sense about... sense about... sense about... sense about... sense about...Homeo sense about... sense about...path sense about...yyy sense about... sense about... sense about... sense about... sense about... sense about... sense about... Homeopathy is marketed as a safe, natural and holistic treatment for a range of ailments and illnesses, including Another way of saying... arthritis, asthma, depression, eczema, diarrhoea, hayfever, 8lacebo 999 a prescription that is inert; that is, it does nothing, headaches, insomnia and toothache. Homeopathic products and like a sugar pill or water. From the Latin, 1 will please.) services have become a large industry. 8lacebo effect 9 an effect, biological, biochemical or Despite this, it has not been embraced by medical science. The physiological, that emerges from an inert treatment because scientific evidence shows that homeopathy acts only as a the patient believes it will work. See page 2 for how placebos work.) placebo and there is no scientific explanation of how it could work any other way. Not to be confused... HomeoHomeopathpathpathicic principles 8roven 999 0proving( is the method homeopaths use to determine the symptoms a substance causes with a view to Homeopathy is based on two beliefs: 1) like cures like; and 2) treating diseases with similar symptoms); after the process a the smaller the dose the more potent the cure. First, homeopaths substance is said to be 0proven(. Scientists use 0proven( to choose a substance that causes the same symptoms as the describe a statement that is, by logic, necessarily true. disease they want to treat. For example, the runny nose and watery eyes of a cold can be recreated by inhaling onion fumes, human and animal waste, dead plants, bacteria and minerals; it so onion juice can form the basis of a homeopathic preparation.
    [Show full text]
  • Illinois Medicaid Preferred Drug List
    Illinois Medicaid Preferred Drug List Effective January 1, 2020 (Updated January 27, 2020) ▪ The Preferred Drug List (PDL) has products listed in groups by drug class, drug name, dosage form, and PDL status ▪ Multi-source drugs are listed by both brand and generic names when applicable ▪ ADHD Agents: Prior authorization required for participants under 6 years of age and participants 19 years of age and older ▪ Spiriva AER 1.25mcg: Prior authorization NOT required for participants ages 6-17 years ▪ Budesonide: Prior authorization NOT required for participants age 7 years and under ▪ Anticonvulsants: Prior authorization NOT required for non-preferred epilepsy agents for those participants with a diagnosis of epilepsy or seizure disorder in Department records ▪ Antipsychotics: Prior authorization required for participants under 8 years of age and long-term care residents ▪ For drugs not found on this list, go to the drug search engine at: www.ilpriorauth.com Page 1 of 92 DOSAGE DRUG CLASS DRUG NAME PDL STATS FORM ADHD / ANTI-NARCOLEPSY AGENTS : AMPHETAMINES ADZENYS ER SUER NON_PREFERRED AMPHETAMINE ER SUER NON_PREFERRED DYANAVEL XR SUER NON_PREFERRED ADZENYS XR-ODT TBED NON_PREFERRED AMPHETAMINE SULFATE TABS NON_PREFERRED EVEKEO TABS NON_PREFERRED EVEKEO ODT TBDP NON_PREFERRED DEXEDRINE CP24 NON_PREFERRED DEXTROAMPHETAMINE SULFATE ER CP24 NON_PREFERRED DEXTROAMPHETAMINE SULFATE SOLN NON_PREFERRED PROCENTRA SOLN NON_PREFERRED DEXTROAMPHETAMINE SULFATE TABS NON_PREFERRED ZENZEDI TABS NON_PREFERRED VYVANSE CAPS PREFERRED VYVANSE CHEW PREFERRED
    [Show full text]
  • Health Effects of Progestins Contained in Cocs, with A
    A PHACTICAL JOURNAL FOR NUHSE PRACTITIONEn5 I i - 1- November 2007 The Official Journal of NPWHj- A 7 .-. Vol. G, No. 11 A Peer-Reviewed Journal &$ Health Effects of Progestins Contained in t COCs, with a -.'P Focus on Norgestimate- -.-I. 21 ? NPWH 2007 ' Annual Conference Abstracts HEALTH EFFECTS OF PROLESTINS CONTAINED IN COCs, WITH A FOGUS ON NORGESTIMATE by Penelope M. Bosarge, MSN, WHNP ased on interviews with more Nurse practitioners (NPs) and their reproductive-aged than 7600 female adolescents and women aged 15 to 44 patients face numerous challenges, particularly when it years, more than 98% who have comes to choosing a method of birth control. If a combined ever had sexual intercourse have used at least one contraceptive oral contraceptive (COC) is judged to be an appropriate meth~d.~The leading method of contraception in the United choice for a given woman, then her NP will need to select a States in 2002 was the Pill, used particular product from among many that are available. by 11.6 million women, and the second leading method was Among the various COC brands on the market, several female sterilization, used by 10.3 million women.2The condom contain norgestimate (NGM), a progestin introduced in was the third-leading method, 1992. Fvteen years of clinical use of NGM-containing used by about 9 million women and their partners. The condom COCs, as well as continued scientz$c investigations of these is the leading method at first intercourse, but the Pill is the products, support their efficacy, safety, and tolerability leading method among women (ie, these products have minimal androgenic and estrogenic younger than 30 yearse2 effects and provide excellent cycle control).
    [Show full text]